Barclays’s Exagen XGN Stock Holding History

Barclays’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.5K	Sell	5,493 -15,734	-74%	-$59.2K	﹤0.01%	4534
2026 Q1	$63.7K	Sell	21,227 -2,374	-10%	-$9.18K	﹤0.01%	4223
2025 Q4	$143K	Buy	23,601 +15,965	+209%	+$145K	﹤0.01%	4468
2025 Q3	$83.9K	Buy	7,636 +2,491	+48%	+$22.1K	﹤0.01%	4659
2025 Q2	$35.9K	Hold	5,145	–	–	﹤0.01%	4756
2025 Q1	$18.5K	Hold	5,145	–	–	﹤0.01%	4799
2024 Q4	$21.1K	Hold	5,145	–	–	﹤0.01%	4917
2024 Q3	$15.9K	Hold	5,145	–	–	﹤0.01%	4925
2024 Q2	$9.36K	Hold	5,145	–	–	﹤0.01%	4524
2024 Q1	$8.18K	Hold	5,145	–	–	﹤0.01%	4824
2023 Q4	$10.2K	Hold	5,145	–	–	﹤0.01%	4968
2023 Q3	$12.5K	Hold	5,145	–	–	﹤0.01%	4269
2023 Q2	$14.9K	Hold	5,145	–	–	﹤0.01%	4176
2023 Q1	$12.5K	Hold	5,145	–	–	﹤0.01%	4719
2022 Q4	$12.3K	Sell	5,145 -71	-1%	-$182	﹤0.01%	4887
2022 Q3	$14K	Hold	5,216	–	–	﹤0.01%	4191
2022 Q2	$30K	Sell	5,216 -1,850	-26%	-$10.8K	﹤0.01%	4247
2022 Q1	$56K	Buy	+7,066	New	+$60.9K	﹤0.01%	4071

Other funds holding XGN

Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FCM

FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

MBAM

Mink Brook Asset Management West Palm Beach, Florida $227M AUM 64.76% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Barclays's XGN Position: Q2 2026 in Review

Barclays reduced its Exagen (XGN) stake by 74% in Q2 2026, selling an estimated $59.2K and leaving 5,493 shares worth $25.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4534.

Barclays first reported a position in XGN in Q1 2022 and has held it in 18 quarters since. The position peaked at $143K in Q4 2025. 57 funds tracked by Wall St. Rank hold XGN as of Q2 2026.

Barclays held 5,493 shares of Exagen worth $25.5K as of Q2 2026.
Barclays sold 15,734 Exagen shares in Q2 2026, an estimated $59.2K.
Exagen made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4534 holding.
Barclays first reported a position in Exagen in Q1 2022 and has held it in 18 quarters since.
Barclays's Exagen position peaked at $143K in Q4 2025.
57 funds tracked by Wall St. Rank held Exagen as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.